More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...

CARsgen’s first enrolled subject in the THANK-u Plus platform-based allogeneic CAR-T trial achieves sCR at week 4: Shanghai, China Tuesday, February 11, 2025, 18:00 Hrs [IST] CA ...

Our Lady of the Lake Cancer Institute is celebrating after successfully completing a bone marrow transplant so rare it has ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

A revolutionary approach to immune therapy has emerged: engineered immune cells that protect healthy tissue without ...

Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Hematopoietic stem cell transplantation (HSCT) is a vital treatment for both malignant and non-malignant disorders in pediatric patients.

For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis ...

Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow ...